0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Special Feature |

Picture of the Month—Diagnosis FREE

[+] Author Affiliations

Section Editor: Samir S. Shah, MD, MSCE

More Author Information
Arch Pediatr Adolesc Med. 2011;165(3):275-276. doi:10.1001/archpediatrics.2011.2-b.
Text Size: A A A
Published online

DENOUEMENT AND DISCUSSION: TELANGIECTASES SECONDARY TO HEREDITARY HEMORRHAGIC TELANGIECTASIA

Telangiectasias represent a direct communication between an artery and a vein without an intervening capillary bed. They tend to be red or purple, to be elevated, and to blanch with pressure. The connection between the high-pressure artery and low-pressure vein tends to be fragile and is prone to spontaneous and recurrent bleeding.

Frequent epistaxis that also occurs in other family members is a common symptom of hereditary hemorrhagic telangiectasia (HHT), also called Rendu-Osler-Weber syndrome. This is an autosomal dominant disorder with varying penetrance and expressivity. It has an estimated incidence of 1 in 5000 persons.1Most patients with HHT have a mutation in 1 of 2 genes that are required for normal angiogenesis.2,3

Abnormal blood vessel development is the hallmark of HHT. Telangiectasias and arteriovenous malformations (AVMs) develop in patients with HHT. Telangiectasias tend to occur on mucocutaneous surfaces (nose, gastrointestinal tract, and skin) (Figure 3). The AVMs develop in larger organ systems (pulmonary, hepatic, brain). The diagnosis of HHT is based on several defining criteria, which may include recurrent epistaxis, telangiectases, visceral AVMs, and family history.4

Place holder to copy figure label and caption
Figure 3.

Red spots on the hands of the patient's father.

Graphic Jump Location

Epistaxis is the most common clinical feature of HHT and occurs in 90% of patients.5Epistaxis occurs secondary to telangiectases that develop on the nasal mucosa (Figure 4). Air passing through the nose leads to dryness and rupture of these fragile blood vessels. Epistaxis leads to iron deficiency anemia in many patients. It can demonstrate a wide range of severity, even within the same family. In some patients, it may be little more than a social nuisance. In others, it can be a source of significant morbidity and potentially life threatening. It is important to remember that 10% of patients will demonstrate no significant epistaxis. These patients, many of whom have seen relatives suffer from nosebleeds all their lives, may mistakenly believe they do not have the disease. This could allow other potentially lethal manifestations of the disease to go undiagnosed.

Place holder to copy figure label and caption
Figure 4.

Intranasal examination of the patient’s father.

Graphic Jump Location

Gastrointestinal bleeding occurs in approximately one-third of patients and is another common cause of iron deficiency anemia.6Mucosal telangiectasias can occur anywhere along the gastrointestinal tract and are frequently visible on the lips and tongue.

Pulmonary AVMs (PAVMs) are found in up to one-third of patients with HHT. In addition, most patients with a PAVM will eventually be diagnosed with the disease. Therefore, HHT should be considered in any patient diagnosed with a PAVM. These PAVMs provide a direct communication between the pulmonary and systemic circulations and thereby produce a right-to-left shunt that can lead to hypoxemia, brain abscesses, or cerebrovascular accidents. Because of the risk associated with these AVMs, patients with known or suspected HHT should undergo screenings for their presence. The PAVMs can be treated with embolization. Patients with known PAVMs or those in whom they have not been excluded should undergo antibiotic prophylaxis prior to having dental procedures to reduce the risk of brain infection.7

Cerebral AVMs affect more than 10% of patients with HHT.8They can cause headache, seizures, and hemorrhage. Hemorrhage due to rupture of cerebral AVMs can lead to long-term disability and sudden death. Magnetic resonance imaging is currently the best way to detect these vascular malformations and should be performed for all patients with known or suspected HHT.

Genetic testing is available for HHT. If a specific mutation is known for a family with HHT, the absence of that mutation in another family member eliminates the need for screening for AVMs in that person. This can be especially helpful for children of affected parents where performing some of these tests may be more difficult and may require sedation or general anesthesia.

Patients with known or suspected HHT should be seen by specialists experienced in the disease. Several centers of excellence exist where a multidisciplinary approach is used. If a referral to these centers is not possible, patients should be seen by a cardiologist for PAVM screening and undergo magnetic resonance imaging of the brain. Those with epistaxis or gastrointestinal bleeding should be seen by an otolaryngologist or gastroenterologist with experience in treating these manifestations of HHT.

Return to Quiz Case.

Correspondence:Scott E. Olitsky, MD, Department of Ophthalmology, Children's Mercy Hospitals and Clinics, University of Missouri–Kansas City School of Medicine, 2401 Gillham Rd, Kansas City, MO 64108 (seolitsky@cmh.edu).

Accepted for Publication: May 21, 2010.

Financial Disclosure:None reported.

Guttmacher  AEMarchuk  DAWhite  RI  Jr Hereditary hemorrhagic telangiectasia. N Engl J Med 1995;333 (14) 918- 924
PubMed
McAllister  KAGrogg  KMJohnson  DW  et al.  Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8 (4) 345- 351
PubMed
Johnson  DWBerg  JNGallione  CJ  et al.  A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Res 1995;5 (1) 21- 28
PubMed
Shovlin  CLGuttmacher  AEBuscarini  E  et al.  Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91 (1) 66- 67
PubMed
Römer  WBurk  MSchneider  W Hereditary hemorrhagic telangiectasia (Osler's disease) [in German]. Dtsch Med Wochenschr 1992;117 (17) 669- 675
PubMed
Kjeldsen  ADKjeldsen  J Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2000;95 (2) 415- 418
PubMed
Faughnan  MEPalda  VAGarcia-Tsao  G  et al.  International guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia [published online June 29, 2009]. J Med Genet
PubMed10.1136/jmg.2009.069013
Fulbright  RKChaloupka  JCPutman  CM  et al.  MR of hereditary hemorrhagic telangiectasia: prevalence and spectrum of cerebrovascular malformations. AJNR Am J Neuroradiol 1998;19 (3) 477- 484
PubMed

Figures

Place holder to copy figure label and caption
Figure 3.

Red spots on the hands of the patient's father.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 4.

Intranasal examination of the patient’s father.

Graphic Jump Location

Tables

References

Guttmacher  AEMarchuk  DAWhite  RI  Jr Hereditary hemorrhagic telangiectasia. N Engl J Med 1995;333 (14) 918- 924
PubMed
McAllister  KAGrogg  KMJohnson  DW  et al.  Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8 (4) 345- 351
PubMed
Johnson  DWBerg  JNGallione  CJ  et al.  A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Res 1995;5 (1) 21- 28
PubMed
Shovlin  CLGuttmacher  AEBuscarini  E  et al.  Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91 (1) 66- 67
PubMed
Römer  WBurk  MSchneider  W Hereditary hemorrhagic telangiectasia (Osler's disease) [in German]. Dtsch Med Wochenschr 1992;117 (17) 669- 675
PubMed
Kjeldsen  ADKjeldsen  J Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2000;95 (2) 415- 418
PubMed
Faughnan  MEPalda  VAGarcia-Tsao  G  et al.  International guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia [published online June 29, 2009]. J Med Genet
PubMed10.1136/jmg.2009.069013
Fulbright  RKChaloupka  JCPutman  CM  et al.  MR of hereditary hemorrhagic telangiectasia: prevalence and spectrum of cerebrovascular malformations. AJNR Am J Neuroradiol 1998;19 (3) 477- 484
PubMed

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles